recurrent or metastatic nasopharyngeal carcinoma (RM-NPC)The First Affiliated Hospital of Nanchang UniversitySun Yat-sen University Cancer Center Institutional Review Boardlocoregional therapyICI rechallenge
…Background Immune checkpoint inhibitor (ICI) rechallenge in recurrent or metastatic nasopharyngeal carcinoma (RM-NPC) is a promising therapeutic strategy. We aim to evaluate the eff…